Filing Flows › Boston Scientific (BSX) › Q3 2026
Boston Scientific (BSX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Boston Scientific (BSX) reported revenue of $5.1B for the third quarter 2026 (Q3 2026), +1% from a year earlier and -6% from the quarter before. Operating margin was 16.1%, net earnings $580M (11.3% of revenue).
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.1B | -6% | +1% |
| Gross profit | $3.4B | -11% | -3% |
| Operating profit | $828M | -30% | -21% |
| Net earnings | $580M | -36% | -23% |
| Operating cash flow | $1.0B | -29% | -22% |
| Free cash flow | $868M | -32% | -25% |
What changed
Revenue was $5.1B in Q3 2026, up 1% year over year and down 6% from the previous quarter. Interventional Cardiology & Vascular Therapies was the largest line at 25% of revenue. Interventional Cardiology & Vascular Therapies added $0.14B year over year (up 12%), 189% of the total change. Watchman declined 6%.
Gross margin was 66.7%, down 3.2 points from Q3 2025. Operating profit was $0.83B, a 16.1% margin (down 4.6 points year over year). Operating profit fell $0.22B even though revenue rose $0.07B versus Q3 2025, so costs grew faster than sales. Operating expenses grew 4% against revenue growth of 1%. The fastest-growing cost line was Other operating costs (+66%). Net earnings were $0.58B, down 23% year over year. The effective tax rate was 20.9%.
Operating cash flow was $1.0B (down 22% year over year), 181% of net earnings. Non-cash charges added back $0.36B of depreciation and amortization and $0.07B of share-based compensation. Capital expenditures of $0.18B left free cash flow of $0.87B.
Questions
What was Boston Scientific's revenue in the third quarter 2026?
Boston Scientific (BSX) reported revenue of $5.1B for the third quarter 2026 (Q3 2026), +1% from a year earlier and -6% from the quarter before.
Was Boston Scientific profitable in the third quarter 2026?
Operating profit was $828M (16.1% of revenue) and net earnings $580M.
Source: Boston Scientific 10-Q on SEC EDGAR.